Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Xeris Biopharma Holdings, Inc.

XERS ✓ COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Pharmaceuticals ·

USA Small Cap Analyst: BUY

Last Close

$10.71

▼ -0.37%

Market Cap $1.95B · Vol 554.94K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: 43.43

Market Cap

$1.95B

Small Cap

Div Yield

N/A

EPS Growth

N/A

YoY

RSI (14)

53.36

Momentum

Beta

0.84

vs Market

52W High

$11.41

6.13% below

52W Low

$5.25

104.00% above

Volume

554.94K

Avg 894.15K

P/B

95.32

Price-to-book

ROE

N/A

Return on equity

Free Float

96.71%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Xeris Biopharma Holdings, Inc. (XERS) stock is Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does XERS pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+5.00%

+12.03%

+27.20%

+74.86%

YTD

+36.43%

+10.30%

+485.25%

+475.81%

Financials & Valuation

TTM · Annual

Total Revenue	$291.85M
Net Income	$554.00K
Revenue Growth (YoY)	+28.74%
Gross Margin	81.70%
Operating Margin	8.53%
Net Profit Margin	0.19%
ROE	N/A
ROA · ROIC	0.16% · 13.58%

P/E Ratio	N/A
Forward P/E (FY1)	43.43
PEG Ratio	24.25
P/S	4.65
P/B	95.32
P/FCF	48.55
EPS Growth	N/A
Outstanding Shares	182.32M

Technical Indicators

50-Day SMA	$9.31
200-Day SMA	$7.50
RSI (14)	53.36
Beta	0.84
52-Week High	$11.41
52-Week Low	$5.25

Volume Today	554.94K
Avg Daily Volume (30D)	894.15K
Relative Volume	0.62x
Volatility (10D)	49.25
Volatility (30D)	57.91
Free Float	96.71%

Analyst Consensus

BUY

Current Price $10.71

Mean Target $12.86

52W Low$5.25 52W High$11.41

Current

Target

$5.25 $11.41

Current Analyst target

+20.05% upside potential · 7 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG012V1MG61

ISINUS98422E1038

CountryUSA

Sub-IndustryPharmaceuticals (NEC)

Earnings DateNov 5, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LLY Eli Lilly and Company +3.19% JNJ Johnson & Johnson -0.73% ABBV AbbVie Inc. +1.41% NVS Novartis AG -0.19% NOVN.S Novartis AG +1.12%

Company Profile

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company focused on improving patient lives by developing and commercializing products across a range of therapies. It has three commercially available products: Recorlev, Gvoke, and Keveyis. Recorlev is for the treatment of endogenous Cushing’s syndrome. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is a therapy for primary periodic paralysis. It also has a pipeline of development programs led by XP-8121, a phase III-ready, once-weekly subcutaneous injection for hypothyroidism. It is pursuing formulation and development partnerships to apply its XeriSol and XeriJect formulation technologies to enhance the drug delivery and clinical profile of other companies’ proprietary drugs and biologics. Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adults with Cushing's syndrome for whom surgery is not an option or has not been curative.